Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...

With zero coding skills, I was able to quickly assemble camera feeds from around the world into a single view. Here's how I did it, and why it's both promising and terrifying for all of us.